Immunotherapy in first-line treatment of recurrent non-small cell lung cancer
For a long time, the standards of first-line drug therapy for patients with advanced non-small-cell lung cancer (NSCLC), excluding cases of mutations of EGFR, ALK and ROS1, were platinum-containing regimens. However, the chemotherapeutic regimes used in the therapy of the first line therapy of NSCLC...
Main Authors: | E. O. Rodionov, S. V. Miller, S. A. Tuzikov, L. A. Efteev, V. A. Markovich, D. S. Miller |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5298 |
Similar Items
-
Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer
by: Chrysanthi Sardeli, et al.
Published: (2020-01-01) -
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
by: Roy Herbst, et al.
Published: (2021-07-01) -
Potential role of immunotherapy in advanced non-small-cell lung cancer
by: de Mello RA, et al.
Published: (2016-12-01) -
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
by: Alessio Cortellini, et al.
Published: (2021-03-01) -
Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
by: Kazuki Gohara, et al.
Published: (2021-01-01)